{"id":904000,"date":"2025-11-03T08:26:30","date_gmt":"2025-11-03T13:26:30","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/tenax-therapeutics-to-participate-in-the-guggenheim-2nd-annual-healthcare-innovation-conference\/"},"modified":"2025-11-03T08:26:30","modified_gmt":"2025-11-03T13:26:30","slug":"tenax-therapeutics-to-participate-in-the-guggenheim-2nd-annual-healthcare-innovation-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/tenax-therapeutics-to-participate-in-the-guggenheim-2nd-annual-healthcare-innovation-conference\/","title":{"rendered":"Tenax Therapeutics to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">CHAPEL HILL, N.C., Nov.  03, 2025  (GLOBE NEWSWIRE) &#8212; Tenax Therapeutics, Inc. (Nasdaq: TENX) (\u201cTenax Therapeutics\u201d or the \u201cCompany\u201d), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, today announced that the Company will present at the Guggenheim 2<sup>nd<\/sup> Annual Healthcare Innovation Conference, which is taking place from November 10-12, 2025, in Boston, MA.<\/p>\n<p align=\"justify\">\n        <strong>Details of presentation:<\/strong>\n      <\/p>\n<p align=\"justify\">\n        <strong>Format:<\/strong> Fireside chat<\/p>\n<p align=\"justify\">\n        <strong>Participants:<\/strong> Chris Giordano, President &amp; Chief Executive Officer, Stuart Rich, M.D., Chief Medical Officer<\/p>\n<p align=\"justify\">\n        <strong>Date and Time:<\/strong> November 10, 2025, at 4:00 p.m. ET<\/p>\n<p align=\"justify\">The live and archived webcast of the presentation will be accessible from the Company\u2019s investor relations\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=nnbNEZ5fJpZ0A6tyyZDsIA9kBJ0ND2LSYBu3cAT7WZ2iL7UowyZL9BFC7dLvAaE25YtUxupSRFJgH65972m51Q6icRdLnRkxCqwmwwvdRwbZASuX3n7mErgjMIChQqf-HYkh9NJNcyB7AbA-rPCQnQ==\" rel=\"nofollow\" target=\"_blank\">webpage<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>About Tenax Therapeutics<\/strong>\n      <\/p>\n<p align=\"justify\">Tenax Therapeutics, Inc. is a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies. The Company owns global rights to develop and commercialize levosimendan, which it is developing for the treatment of PH-HFpEF, the most prevalent form of pulmonary hypertension globally, for which no product has been approved to date. For more information, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=AY1qJJ20PO9nTsFFueUhKipaqN9Jyp55oifm_k_aoYLWsz0KtcbwJZNN20Ov4zvBBvQNBNYXWo5J6U4sf0wkgQ==\" rel=\"nofollow\" target=\"_blank\">tenaxthera.com<\/a>. Tenax Therapeutics\u2019 common stock is listed on The Nasdaq Stock Market LLC under the symbol \u201cTENX\u201d.<\/p>\n<p align=\"justify\">\n        <strong>Contact:<\/strong>\n      <\/p>\n<p align=\"justify\">Investor and Media:<\/p>\n<p align=\"justify\">Argot Partners<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=AY1qJJ20PO9nTsFFueUhKsr0z2yneXsxDKJHRzXRLItDsg8V--PArsfhjPei4OfbZ5pdJTdgyLCBOoLUNd8GPh5-PD_VZw3YSasnJVqMACoNYc4HDNePEdUShKbkV8vr\" rel=\"nofollow\" target=\"_blank\">tenax@argotpartners.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2NjM4MSM3MjM1OTQ3IzIwMTAwNDE=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/Y2U1NTQxMTktNzZmMC00YjYwLWI5OTUtNzYxNTM4YjcxZTNiLTEwMjE2MTQtMjAyNS0xMS0wMy1lbg==\/tiny\/Tenax-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>CHAPEL HILL, N.C., Nov. 03, 2025 (GLOBE NEWSWIRE) &#8212; Tenax Therapeutics, Inc. (Nasdaq: TENX) (\u201cTenax Therapeutics\u201d or the \u201cCompany\u201d), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, today announced that the Company will present at the Guggenheim 2nd Annual Healthcare Innovation Conference, which is taking place from November 10-12, 2025, in Boston, MA. Details of presentation: Format: Fireside chat Participants: Chris Giordano, President &amp; Chief Executive Officer, Stuart Rich, M.D., Chief Medical Officer Date and Time: November 10, 2025, at 4:00 p.m. ET The live and archived webcast of the presentation will be accessible from the Company\u2019s investor relations\u00a0webpage. About Tenax Therapeutics Tenax Therapeutics, Inc. is a Phase 3, development-stage pharmaceutical company using clinical &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/tenax-therapeutics-to-participate-in-the-guggenheim-2nd-annual-healthcare-innovation-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Tenax Therapeutics to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-904000","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Tenax Therapeutics to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/tenax-therapeutics-to-participate-in-the-guggenheim-2nd-annual-healthcare-innovation-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Tenax Therapeutics to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"CHAPEL HILL, N.C., Nov. 03, 2025 (GLOBE NEWSWIRE) &#8212; Tenax Therapeutics, Inc. (Nasdaq: TENX) (\u201cTenax Therapeutics\u201d or the \u201cCompany\u201d), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, today announced that the Company will present at the Guggenheim 2nd Annual Healthcare Innovation Conference, which is taking place from November 10-12, 2025, in Boston, MA. Details of presentation: Format: Fireside chat Participants: Chris Giordano, President &amp; Chief Executive Officer, Stuart Rich, M.D., Chief Medical Officer Date and Time: November 10, 2025, at 4:00 p.m. ET The live and archived webcast of the presentation will be accessible from the Company\u2019s investor relations\u00a0webpage. About Tenax Therapeutics Tenax Therapeutics, Inc. is a Phase 3, development-stage pharmaceutical company using clinical &hellip; Continue reading &quot;Tenax Therapeutics to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/tenax-therapeutics-to-participate-in-the-guggenheim-2nd-annual-healthcare-innovation-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-03T13:26:30+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2NjM4MSM3MjM1OTQ3IzIwMTAwNDE=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tenax-therapeutics-to-participate-in-the-guggenheim-2nd-annual-healthcare-innovation-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tenax-therapeutics-to-participate-in-the-guggenheim-2nd-annual-healthcare-innovation-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Tenax Therapeutics to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference\",\"datePublished\":\"2025-11-03T13:26:30+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tenax-therapeutics-to-participate-in-the-guggenheim-2nd-annual-healthcare-innovation-conference\\\/\"},\"wordCount\":202,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tenax-therapeutics-to-participate-in-the-guggenheim-2nd-annual-healthcare-innovation-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU2NjM4MSM3MjM1OTQ3IzIwMTAwNDE=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tenax-therapeutics-to-participate-in-the-guggenheim-2nd-annual-healthcare-innovation-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tenax-therapeutics-to-participate-in-the-guggenheim-2nd-annual-healthcare-innovation-conference\\\/\",\"name\":\"Tenax Therapeutics to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tenax-therapeutics-to-participate-in-the-guggenheim-2nd-annual-healthcare-innovation-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tenax-therapeutics-to-participate-in-the-guggenheim-2nd-annual-healthcare-innovation-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU2NjM4MSM3MjM1OTQ3IzIwMTAwNDE=\",\"datePublished\":\"2025-11-03T13:26:30+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tenax-therapeutics-to-participate-in-the-guggenheim-2nd-annual-healthcare-innovation-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tenax-therapeutics-to-participate-in-the-guggenheim-2nd-annual-healthcare-innovation-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tenax-therapeutics-to-participate-in-the-guggenheim-2nd-annual-healthcare-innovation-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU2NjM4MSM3MjM1OTQ3IzIwMTAwNDE=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU2NjM4MSM3MjM1OTQ3IzIwMTAwNDE=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tenax-therapeutics-to-participate-in-the-guggenheim-2nd-annual-healthcare-innovation-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Tenax Therapeutics to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Tenax Therapeutics to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/tenax-therapeutics-to-participate-in-the-guggenheim-2nd-annual-healthcare-innovation-conference\/","og_locale":"en_US","og_type":"article","og_title":"Tenax Therapeutics to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference - Market Newsdesk","og_description":"CHAPEL HILL, N.C., Nov. 03, 2025 (GLOBE NEWSWIRE) &#8212; Tenax Therapeutics, Inc. (Nasdaq: TENX) (\u201cTenax Therapeutics\u201d or the \u201cCompany\u201d), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, today announced that the Company will present at the Guggenheim 2nd Annual Healthcare Innovation Conference, which is taking place from November 10-12, 2025, in Boston, MA. Details of presentation: Format: Fireside chat Participants: Chris Giordano, President &amp; Chief Executive Officer, Stuart Rich, M.D., Chief Medical Officer Date and Time: November 10, 2025, at 4:00 p.m. ET The live and archived webcast of the presentation will be accessible from the Company\u2019s investor relations\u00a0webpage. About Tenax Therapeutics Tenax Therapeutics, Inc. is a Phase 3, development-stage pharmaceutical company using clinical &hellip; Continue reading \"Tenax Therapeutics to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/tenax-therapeutics-to-participate-in-the-guggenheim-2nd-annual-healthcare-innovation-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2025-11-03T13:26:30+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2NjM4MSM3MjM1OTQ3IzIwMTAwNDE=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tenax-therapeutics-to-participate-in-the-guggenheim-2nd-annual-healthcare-innovation-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tenax-therapeutics-to-participate-in-the-guggenheim-2nd-annual-healthcare-innovation-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Tenax Therapeutics to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference","datePublished":"2025-11-03T13:26:30+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tenax-therapeutics-to-participate-in-the-guggenheim-2nd-annual-healthcare-innovation-conference\/"},"wordCount":202,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tenax-therapeutics-to-participate-in-the-guggenheim-2nd-annual-healthcare-innovation-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2NjM4MSM3MjM1OTQ3IzIwMTAwNDE=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tenax-therapeutics-to-participate-in-the-guggenheim-2nd-annual-healthcare-innovation-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/tenax-therapeutics-to-participate-in-the-guggenheim-2nd-annual-healthcare-innovation-conference\/","name":"Tenax Therapeutics to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tenax-therapeutics-to-participate-in-the-guggenheim-2nd-annual-healthcare-innovation-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tenax-therapeutics-to-participate-in-the-guggenheim-2nd-annual-healthcare-innovation-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2NjM4MSM3MjM1OTQ3IzIwMTAwNDE=","datePublished":"2025-11-03T13:26:30+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tenax-therapeutics-to-participate-in-the-guggenheim-2nd-annual-healthcare-innovation-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/tenax-therapeutics-to-participate-in-the-guggenheim-2nd-annual-healthcare-innovation-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tenax-therapeutics-to-participate-in-the-guggenheim-2nd-annual-healthcare-innovation-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2NjM4MSM3MjM1OTQ3IzIwMTAwNDE=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2NjM4MSM3MjM1OTQ3IzIwMTAwNDE="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tenax-therapeutics-to-participate-in-the-guggenheim-2nd-annual-healthcare-innovation-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Tenax Therapeutics to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/904000","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=904000"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/904000\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=904000"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=904000"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=904000"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}